From Wikipedia, the free encyclopedia

Sodium nitroprusside
Systematic (IUPAC) name
sodium nitroferricyanide
Identifiers
CAS number	13755-38-9
ATC code	C02DD01
PubChem	26256
DrugBank	APRD01143
Chemical data
Formula	C5N6Na2O
Mol. mass	261.92
Pharmacokinetic data
Bioavailability	?
Metabolism	circulatory
Half life	2 minutes (metabolites: several days)
Excretion	Renal
Therapeutic considerations
Pregnancy cat.	C
Legal status	℞ Prescription only
Routes	IV

Sodium nitroprusside
General
Systematic name	Sodium pentacyanonitrosylferrate(III)
Other names	Sodium nitroprusside Sodium nitroferricyanide Sodium pentacyanonitrosylferrate SNP Sodium nitroferricyanide(III) dihydrate Sodium nitroprusside dihydrate
Molecular formula	Na2[Fe(CN)5NO]·2H2O
Molar mass	297.95 g mol−1 (dihydrate)
Appearance	red powder
CAS number	[13755-38-9]
Properties
Solubility in water	good
Other solvents	soluble in Ethanol
Structure
Coordination geometry	octahedral at Fe
Main hazards	Cyanide poisoning
R/S statement	R: 25 S: 45
RTECS number	LJ8750000

Sodium nitroprusside is the chemical compound with the formula Na₂[Fe(CN)₅NO]·2H₂O.^[1] This salt serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles). Sodium nitroprusside is often administered intravenously to patients who are experiencing a hypertensive emergency.

"Nitroprusside" is an anion that is usually available as the dihydrated disodium salt, Na₂[Fe(CN)₅NO]·2H₂O. This red solid dissolves in water, and to a lesser extent in alcohol to give a solution containing the dianion [Fe(CN)₅NO]²⁻. This metal nitrosyl complex is the active agent. In this anion, the iron is octahedral, surrounded by five tightly bound cyanide ligands and one linear nitric oxide ligand. When the linear nitrosyl ligand is assigned a single positive charge, the iron is assigned an oxidation state of 2+. This is a paramagnetic ion.^{[citation needed]} Its chemical reactions have been studied intensively.^[2]

It reduces both total peripheral resistance as well as venous return, thus decreasing both preload and afterload. For this reason, it can be used in severe cardiogenic heart failure where this combination of effects can act to increase cardiac output. In situations where cardiac output is normal; the effect is to reduce blood pressure.

Nitroprusside is light-sensitive, and breaks down in sunlight, producing cyanide.

Despite its toxicity, nitroprusside is still used because it remains an effective drug in certain clinical circumstances such as malignant hypertension or for rapid control of blood pressure during vascular surgery and neurosurgery.

Nitroprusside is contraindicated in patients with renal failure.

Its mechanism of action appears to be liberation of nitric oxide (NO), converting Haemoglobin to cyanomethaemaglobin. Nitroprusside also releases cyanide ions which are converted in the liver to thiocyanate by the enzyme rhodanase, a reaction which requires a sulfur donor such as thiosulfate. Thiocyanate is then excreted by the kidney. In the absence of sufficient thiosulfate, cyanide ions can quickly reach toxic levels.

The half-life of nitroprusside is less than 10 minutes although thiocyanate has an excretion half life of several days. The duration of treatment should not exceed 72 hours and thiocyanate plasma concentrations should be monitored.

Sodium nitroprusside (often abbreviated SNP) is frequently used in vascular research to test endothelium-independent vasodilation. One method of administering SNP is by iontophoresis. This allows local administration of the drug, preventing the systemic effects listed above but still causing local microvascular vasodilation. NO liberated from the SNP diffuses into the vascular smooth muscle causing relaxation and subsequent vasodilatation. This vasodilatation is quantified by various techniques. This role in the treatment of hypetension was first performed at the Cleveland Clinic. ^[3]